0 items USD 0.00Amgen and Roche to Lead Global Bispecific Antibodies Market
According to new pipeline report analysis - based on the number of projects on the profiles of 90 drug candidates in development, and 237 scientific references - the leading companies in bioengineered antibodies market are:
Amgen
Roche
GlaxoSmithKline
Pfizer
Xencor
MacroGenics
Genmab
Immunocre
Harpoon Therapeutics
TeneoBio
Affimed Therapeutics
Immunotherapy of cancer with T-cells or NK cells is an area of great interest for the biopharmaceutical industry. Chimeric antigen receptor (CAR) engineered T-cell or NK cells represent one treatment modality under clinical evaluation, but the majority of Big Pharma prefers the engagement of T-cells or NK cells by recombinant monoclonal antibodies as off-the-shelf products. As our new report finds, only a few major pharmaceutical companies have clinically validated in-house bispecific antibody technology, partnering with technology providing companies is of great importance.
According to new antibody research report, within three years, the number of clinical stage T-cell and NK cell engagers has more than doubled and further product candidates will enter clinical evaluation in the near future.
The Definitions:
A T cell is a subtype of a white blood cell which develops in the thymus gland and pivotal to immune response, these cells can be extracted from bone marrow. Natural killer cells, or NK cells, are a type of cytotoxic lymphocyte critical to the innate immune system. Mature NK cells can be obtained in vitro from CD34(+) cells isolated from umbilical cord blood or from bone marrow.
The Bispecific monoclonal antibody is also known as (BsMAb, BsAb) - an artificial protein or synthetic protein that mimic the function and structure of true proteins. This protein can simultaneously bind to two different types of antigen (foreign substances that stimulate the immune system to produce antibodies). Artificial protein performs complex functions such as transferring electrons or breaking chemical bonds. BsMAb can be manufactured in several structural formats, and current applications have been explored for cancer immunotherapy and drug delivery.
The Antibody Technology report will show you that there are plenty of opportunities for players in the field, including major pharmaceuticals, technology providers and investors.
Amgen’s Bispecific T-Cell Engager Pipeline
Amgen's bispecific T cell engager (BiTE®) platform across hematologic malignancies and solid tumors, including for the first time, in prostate cancer. BiTE molecules are designed to engage patients' T cells to tumor-specific antigens, activating the cytotoxic potential of T cells with the goal of eliminating detectable cancer. Updated results will also be presented from a Phase 1 dose escalation study evaluating. Bispecific T cell engager (BiTE®) technology is a targeted immuno-oncology platform that is designed to engage patients' own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. (Source: Company Press Release)
Roche’s Bispecific T-Cell Engager Pipeline
Roche, Pharma Research Early Development (pRED) has designed a new format for bispecific antibodies, called CrossMAbs (where MAb stands for Monoclonal Antibody). In contrast to 50 more or less artificial formats of bispecific antibodies engineered over the past two decades technologies,CrossMAbs have no chemical linkers or connectors, that wouldn’t be part of a natural antibody. Roche researchers claim that they produce CrossMAbs with the same biology used by nature and the same manufacturing process in mammalian cells established 30 years ago for monoclonal antibodies. (Source: Company Press Release)
Learn more about profiles of 58 clinical stage and 25 non-clinical development stage T-cell and NK cell engaging bispecific antibodies form the basis of:
- Competitor analysis for a given target
- Description of popular targets and bispecific antibody technologies
- Discussion of product candidates from emerging next-generation technologies
- Learning from clinical experience in hematologic and solid tumor indications.
Email a colleague
Printer version
Send by email
About The Author
Table of Contents
1 . Related Reports
E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H1 2019
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H1 2019
Prostaglandin D2 Receptor 2 - Pipeline Review, H1 2019
C-X-C Chemokine Receptor Type 4 - Pipeline Review, H1 2019
C-X-C Chemokine Receptor Type 2 - Pipeline Review, H1 2019
Bone Marrow Transplant Rejection - Pipeline Review, H1 2019
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals an industry analysis of technologies, stakeholders, deals & trends
Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends
